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mGluR5 antagonism inhibits 
cocaine reinforcement and relapse 
by elevation of extracellular 
glutamate in the nucleus 
accumbens via a CB1 receptor 
mechanism
Xia Li1,2, Xiao-Qing Peng  2,3, Chloe J. Jordan2, Jie Li1,2, Guo-Hua Bi2, Yi He2, Hong-Ju Yang2, 
Hai-Ying Zhang2, Eliot L. Gardner2 & Zheng-Xiong Xi2
Metabotropic glutamate receptor 5 (mGluR5) antagonism inhibits cocaine self-administration and 
reinstatement of drug-seeking behavior. However, the cellular and molecular mechanisms underlying 
this action are poorly understood. Here we report a presynaptic glutamate/cannabinoid mechanism 
that may underlie this action. Systemic or intra-nucleus accumbens (NAc) administration of the 
mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) dose-dependently reduced cocaine 
(and sucrose) self-administration and cocaine-induced reinstatement of drug-seeking behavior. The 
reduction in cocaine-taking and cocaine-seeking was associated with a reduction in cocaine-enhanced 
extracellular glutamate, but not cocaine-enhanced extracellular dopamine (DA) in the NAc. MPEP 
alone, when administered systemically or locally into the NAc, elevated extracellular glutamate, but 
not DA. Similarly, the cannabinoid CB1 receptor antagonist, rimonabant, elevated NAc glutamate, 
not DA. mGluR5s were found mainly in striatal medium-spiny neurons, not in astrocytes, and MPEP-
enhanced extracellular glutamate was blocked by a NAc CB1 receptor antagonist or N-type Ca++ 
channel blocker, suggesting that a retrograde endocannabinoid-signaling mechanism underlies MPEP-
induced glutamate release. This interpretation was further supported by our findings that genetic 
deletion of CB1 receptors in CB1-knockout mice blocked both MPEP-enhanced extracellular glutamate 
and MPEP-induced reductions in cocaine self-administration. Together, these results indicate that 
the therapeutic anti-cocaine effects of mGluR5 antagonists are mediated by elevation of extracellular 
glutamate in the NAc via an endocannabinoid-CB1 receptor disinhibition mechanism.
Drug addiction is a chronic brain disease characterized by drug-induced euphoria, craving and relapse to 
drug-seeking behavior after abstinence. There are no approved medications available for the treatment of 
cocaine addiction. Recent studies suggest that the metabotropic glutamate receptor 5 (mGluR5) is involved in 
cocaine reward and addiction1,2, as genetic deletion or pharmacological blockade of mGluR5 inhibits cocaine 
self-administration1,3–8 and cocaine-induced reinstatement of drug-seeking behavior7–11. These data suggest 
that mGluR5 could be an important target in medication development for the treatment of cocaine addic-
tion. However, the cellular and molecular mechanisms through which mGluR5 modulates cocaine-taking and 
cocaine-seeking behaviors are poorly understood.
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It is well documented that cocaine self-administration and reinstatement of drug-seeking behaviors are asso-
ciated with cocaine-induced increases in extracellular dopamine (DA) and glutamate in the nucleus accumbens 
(NAc)7,8,12–14, which subsequently activates postsynaptic DA (D1-like, D2-like) and glutamate receptors2,15–19. 
Glutamate receptors include ionotropic (NMDA, AMPA, kainate) and metabotropic glutamate receptors 
(mGluR1-mGluR8). It is unclear how selective blockade of the mGluR5 subtype, without interruption of DA 
receptors and many other glutamate receptor subtypes, robustly inhibits cocaine self-administration and rein-
statement of cocaine-seeking behaviors.
mGluR5s are found mainly in striatal medium-spiny neurons (MSNs)20–23. mGluR5 stimulation activates 
phospholipase C (PLC), resulting in the generation of inositol triphosphate (IP3) and diacylglycerol (DAG), which 
activates protein kinase C (PKC)24. Microinjections of the mGluR1/5 agonist DHPG18 or the selective mGluR5 
agonist CHPG10 into the NAc reinstates cocaine-seeking behavior, while microinjections of a PLC or PKC inhib-
itor attenuate cocaine-induced reinstatement18,25, suggesting an important role of NAc mGluR5 in reinstatement 
of drug-seeking. However, the neural mechanisms by which mGluR5s in MSNs modulate cocaine-taking and 
cocaine-seeking behaviors are unknown.
In vitro electrophysiological evidence indicates that mGluR5 activation produces short- or long-term depres-
sion of glutamate release from neuronal terminals in the striatum via a retrograde endocannabinboid (eCB) mech-
anism. Specifically, stimulation of mGluR5 results in eCB release from postsynaptic MSN neurons, with released 
eCB then diffusing in retrograde fashion to activate presynaptic CB1 receptors and inhibit Ca++-dependent vesic-
ular glutamate release in the NAc and the dorsal striatum26–29. However, little is known whether this retrograde 
eCB mechanism underlies mGluR5 function at behavioral level in vivo. Here we hypothesized that mGluR5s may 
modulate cocaine self-administration and reinstatement of cocaine-seeking behaviors by regulating presynaptic 
glutamate release via a retrograde eCB-CB1 receptor mechanism. To test this hypothesis, we used multiple ani-
mal models of drug self-administration, combined with in vivo brain microdialysis and transgenic CB1 recep-
tor knockout approaches, to study the interaction of cocaine, mGluR5 and CB1 receptors on drug-taking and 
drug-seeking behavior and on extracellular DA and glutamate levels in the NAc.
Results
MPEP inhibits cocaine self-administration and cocaine-induced reinstatement of drug-seeking 
behavior. We have recently reported that the mGluR5 antagonists MTEP, fenobam and MFZ 10−7 are effec-
tive in attenuation of cocaine self-administration and relapse to drug-seeking behavior in rats7,8. In this study, we 
used MPEP, a prototypic mGluR5 antagonist30, to systemically evaluate its effects on cocaine self-administration 
and reinstatement of drug-seeking behavior. Figure 1A shows the timeline of this experiment. After cocaine 
self-administration was stabilized, the experimental animals were divided into three dose groups to observe the 
effects of MPEP on cocaine self-administration. Figure 1B shows that pretreatment with MPEP (10, 20 mg/kg, 
i.p., 30 min prior to self-administration) did not significantly decrease the total number of cocaine infusions 
within the daily 3-h session under a fixed-ratio 2 (FR2) reinforcement condition (one-way ANOVA, F2,17 = 1.23, 
p > 0.05). However, when we examined the time courses of cocaine self-administration during the 3-h session, we 
found that MPEP significantly inhibited cocaine self-administration only within the first hour of testing (Fig. 1C, 
two-way ANOVA with repeated measures for time: treatment, F2,17 = 12.72, p < 0.001, time, F2,34 = 0.61, p > 0.05, 
treatment × time interaction, F4,34 = 3.57, p < 0.05). After completing the first drug testing, the rats were contin-
ually trained for cocaine self-administration until responding was re-stabilized. Then the animals were randomly 
divided into three dose groups again to observe the effects of intra-NAc microinjections of MPEP on cocaine 
self-administration. Figure 1D shows that intra-NAc local administration of MPEP (vehicle, 1, 3 μg/side) also 
dose-dependently inhibited cocaine self-administration (F2,16 = 3.97, p < 0.05).
To determine whether blockade of mGluR5 alters the rewarding strength of cocaine, we used cocaine 
self-administration procedures under a progressive-ratio (PR) reinforcement schedule to examine the effects of 
MPEP on the break-point level, an index of reward strength31, for cocaine self-administration in an additional 
group of rats. Figure 1E shows that systemic administration of MPEP significantly and dose-dependently lowers 
the break-point for cocaine self-administration (F1,18 = 4.65, p < 0.05), suggesting reduced cocaine reward after 
mGluR5 blockade31. This reduction in cocaine self-administration is not likely due to MPEP-induced sedation or 
nonspecific locomotor impairment since MPEP, at the same doses as used in cocaine self-administration, failed 
to alter oral sucrose self-administration under FR2 reinforcement (Fig. 1F), but decreased the break-point level 
for sucrose self-administration under PR reinforcement (Fig. 1G).
We then examined the effects of MPEP on reinstatement of drug-seeking behavior triggered by cocaine prim-
ing, re-exposure to cocaine-associated cues, or footshock stress in additional groups of rats. The initial cocaine 
self-administration under FR1 and FR2 reinforcement was the same as described above. After responding was 
stabilized, rats underwent the extinction phase, during which lever presses did not produce any consequence, 
i.e., no cocaine infusions, no cocaine-associated cue lights and no tones were presented. After stable extinc-
tion criteria were met (defined as ≤10 active lever presses during three consecutive 3-h sessions), the animals 
were divided into three groups to observe the effects of MPEP on reinstatement responding produced by three 
different triggers. Strikingly, pretreatment with MPEP (vehicle, 10, 20, 30 mg/kg, 30 min prior to testing) selec-
tively inhibited cocaine-induced reinstatement of drug-seeking behavior in a dose-dependent manner (Fig. 1H, 
F3,27 = 10.04, p < 0.001), but had no effect on cue-induced reinstatement (Fig. 1I, F3,28 = 0.28, p > 0.05) or foot-
shock stress-induced reinstatement (Fig. 1J, F3,24 = 0.39, p > 0.05).
MPEP attenuates cocaine-enhanced extracellular NAc glutamate, but not DA. We next carried 
out brain in vivo microdialysis in additional groups of rats with the same history of cocaine self-administration 
and extinction training, to measure cocaine-induced changes in extracellular DA and glutamate in the NAc in 
the absence or presence of MPEP pretreatment. Figure 2 shows that cocaine (10 mg/kg, i.p.) priming significantly 
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increased extracellular NAc DA (Fig. 2A,C) and glutamate (Fig. 2B,D). Since MPEP pretreatment altered basal 
levels of extracellular glutamate before cocaine priming injections (Fig. 2B), we renormalized the data over new 
baselines taken immediately before cocaine injections (Fig. 2C,D). We found that MPEP pretreatment selec-
tively attenuated cocaine-induced increases in glutamate (Fig. 2D, F2,21 = 4.15, p < 0.05), but not in DA (Fig. 2C, 
Figure 1. Effects of the mGluR5 antagonist MPEP on cocaine self-administration and reinstatement of drug-
seeking behavior in rats. (A) Diagram showing the general experimental procedures. (B) Effects of systemic 
administration of MPEP (10, 20 mg/kg) on the total number of cocaine infusions during daily 3 h session; 
(C) Time course of cocaine self-administration within daily 3 h session, illustrating that MPEP significantly 
inhibited cocaine self-administration in the first hour of self-administration sessions. (D) Intra-NAc local 
administration of MPEP also inhibited cocaine self-administration. (E) Systemic administration of MPEP 
dose-dependently lowered the break-point for cocaine self-administration under PR reinforcement. (F/G) 
Systemic administration of MPEP failed to alter oral sucrose self-administration under FR2 reinforcement (F) 
but decreased the break-point for sucrose self-administration under PR reinforcement (G). (H/I/J) Systemic 
administration of MPEP dose-dependently inhibited reinstatement of drug-seeking behavior triggered by 
cocaine (H), but not by cues (I) or footshock stress (J). *p < 0.05, **p < 0.01, ***p < 0.001, compared to vehicle 
control group.
www.nature.com/scientificreports/
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F2,21 = 0.82, p > 0.05), suggesting that a glutamate mechanism may underlie MPEP antagonism of cocaine-taking 
and cocaine-seeking behavior.
MPEP alone increases extracellular glutamate, but not DA. We next examined the effects of MPEP 
alone on extracellular DA and glutamate in the NAc. Figure 3(A,B) shows that systemic administration of MPEP 
failed to alter extracellular NAc DA (Fig. 3A: F2,14 = 1.76, p > 0.05), but dose-dependently elevated extracellular 
levels of glutamate (Fig. 3B, F2,17 = 3.63, p < 0.05). Figure 3(C,D) shows that local administration of MPEP into the 
NAc similarly elevated extracellular glutamate (Fig. 3D, F11,55 = 3.04, p < 0.01), but not DA (Fig. 3C: F11,66 = 1.72, 
p > 0.05). Surprisingly, intra-NAc local perfusion of (R,S)-2-chloro-5-hydroxyphenylglycine (CHPG), a selective 
mGluR5 agonist, did not significantly alter extracellular levels of DA (Fig. 3C: F11,66 = 1.12, p > 0.05) or glutamate 
(Fig. 3D: F11,44 = 0.29, p > 0.05).
MPEP-enhanced extracellular glutamate is Ca++ channel-dependent. How does mGluR5 antag-
onism elevate extracellular glutamate? To address this question, we first examined the cellular distributions of 
mGluR5 in the striatum. We found that mGluR5-immunostaining was detected mainly in cell bodies of striatal 
neurons, not in GFAP-labeled astrocytes (Fig. 4A,B), suggesting that mGluR5s are located mainly on postsynaptic 
medium-spiny neurons in the NAc and MPEP-enhanced glutamate release may be derived from neuronal, not 
glial, sources.
To further explore this possibility, we examined the effects of tetrodotoxin (TTX, a voltage-dependent Na+ 
channel blocker) or ω-conotoxin GVIA (a N-type Ca++ channel blocker) on MPEP-enhanced extracellular gluta-
mate. Figure 4C shows that intra-NAc local perfusion of TTX (1 μM) did not alter basal or MPEP-enhanced glu-
tamate. In contrast, intra-NAc local perfusion of ω-conotoxin GVIA (1, 2.5 μM) modestly lowered basal levels of 
Figure 2. Effects of MPEP on cocaine-induced changes in extracellular DA and glutamate in the NAc. (A,B) 
Effects of MPEP and cocaine on extracellular DA (A) and glutamate (B) in the NAc in rats after cocaine self-
administration and extinction. (C,D) Cocaine-induced % changes in extracellular DA or glutamate over new 
baseline (mean value of two samples before cocaine injection) in the presence or absence of MPEP, illustrating 
that MPEP pretreatment significantly attenuated cocaine-enhanced glutamate, but not DA, in a dose-dependent 
manner. **p < 0.01, ***p < 0.001, compared to pre-cocaine baseline; #p < 0.05, compared to vehicle control 
group. The inserted boxes in Panels (C,D) show the areas from which the data were subjected to statistical 
analysis.
www.nature.com/scientificreports/
5ScIeNTIfIc RepoRts |  (2018) 8:3686  | DOI:10.1038/s41598-018-22087-1
extracellular glutamate by itself, and co-administration of ω-conotoxin GVIA blocked MPEP-induced increases 
in NAc glutamate (Fig. 4D). These findings suggest that MPEP-enhanced extracellular glutamate is neuronal 
terminal Ca++ channel-dependent, but not action potential-dependent.
Presynaptic CB1 receptors modulate glutamate release. How does postsynaptic mGluR5 antago-
nism facilitate presynaptic glutamate release in a Ca++ channel-dependent manner? As stated above, stimulation 
of postsynaptic mGluR5s in the striatum may inhibit presynaptic glutamate release via a retrograde endocan-
nabinoid mechanism, which is Ca++ channel-dependent, but not Na+-channel or action potential-dependent 
(Fig. 4E)26,27,29,32. We therefore hypothesized that this retrograde eCB-CB1R mechanism may mediate 
MPEP-induced increases in glutamate release (Fig. 4E). To test this hypothesis, we examined whether block-
ade of CB1 receptors produced a similar effect as MPEP did under the same experimental conditions. Figure 5 
shows that systemic administration of the CB1 receptor antagonist SR141716A (rimonabant) (2, 10 mg/kg, i.p.) 
also failed to alter extracellular DA (Fig. 5A, F2,17 = 1.02, p > 0.05), but significantly increased extracellular glu-
tamate (Fig. 5B, F2,17 = 4.85, p < 0.05). Consistent with these findings, intra-NAc local perfusion of SR141716A 
produced the same effects as systemic administration of MPEP, that is, no effect on extracellular DA (Fig. 5C) 
but an increase in extracellular glutamate (Fig. 5D, F11,88 = 3.95, p < 0.001). To further determine whether 
MPEP-induced increases in glutamate release is mediated by inactivation of CB1 receptors, SR141716A was 
locally and continuously perfused into the NAc to block the NAc CB1 receptor and then co-administered with 
MPEP. We found that the presence of NAc SR141716A completely blocked MPEP-induced increases in glutamate 
(Fig. 5E,F). These data suggest that MPEP-enhanced glutamate release is CB1R-dependent, and CB1R inactiva-
tion leads to an increase in presynaptic glutamate release.
CB1R deletion blocks MPEP’s action in glutamate release and cocaine self-administration. 
Finally, we examined whether genetic deletion of CB1 receptors in CB1-KO mice blocks MPEP action. Figure 6 
shows that systemic administration of MPEP (10 mg/kg, i.p.) did not significantly alter extracellular DA (Fig. 6A, 
Figure 3. Effects of MPEP alone on basal extracellular DA and glutamate in the NAc in rats. (A,B) Systemic 
administration of MPEP did not alter basal extracellular DA, but significantly elevated extracellular glutamate. 
(C,D) Intra-NAc local perfusion of MPEP failed to alter extracellular DA, but elevated extracellular glutamate in 
a concentration-dependent manner. Intra-NAc local perfusion of CHPG did not produce significant changes in 
DA or glutamate. *p < 0.05, compared to pre-treatment baseline.
www.nature.com/scientificreports/
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F1,12 = 0.31, p > 0.05), but significantly elevated extracellular glutamate (Fig. 6B, F1,12 = 6.58, p < 0.05) in wild-type 
(WT) mice. However, in CB1-KO mice MPEP did not alter either extracellular DA or glutamate in the NAc. 
Similarly, systemic administration of MPEP (10, 20, 30 mg/kg) significantly and dose-dependently inhibited 
Figure 4. Neural mechanisms underlying MPEP-enhanced extracellular glutamate in the NAc. (A,B) The 
cellular distributions of mGluR5s, illustrating that mGluR5-immunostaining was detected mainly in striatal 
neurons, not in GFAP-labeled astrocytes. (C,D) Intra-NAc local perfusion of TTX had no effect, while 
ω-conotoxin GVIA blocked MPEP-enhanced extracellular glutamate. TTX alone failed to alter extracellular 
glutamate, while ω-conotoxin GVIA alone significantly lowered extracellular glutamate. (E) Diagram showing 
the retrograde eCB-CB1 receptor mechanism underlying MPEP-enhanced glutamate release and the targets of 
the pharmacological agents used in this study. *p < 0.05, **p < 0.01, compared to pre-treatment baseline.
www.nature.com/scientificreports/
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cocaine self-administration in WT (Fig. 6C, F3,18 = 4.85, p < 0.01) mice, but not in CB1-KO mice (Fig. 6D, 
F3,15 = 1.02, p > 0.05). Figure 6E shows the time courses of mouse cocaine self-administration in the absence or 
presence of MPEP, illustrating that the inhibitory effect of MPEP occurs mainly in the first hour of the daily 3 h 
session in WT mice, but not in CB1-KO mice (Fig. 6F).
Discussion
Intravenous drug self-administration and reinstatement of drug-seeking behaviors are the most commonly used 
animal models for studying drug reward and relapse33. In the present study, we found that systemic or local 
Figure 5. Effects of the CB1 receptor antagonist SR141716A on basal extracellular DA and glutamate in the 
NAc. (A,B) Systemic administration of SR141716A did not alter basal extracellular DA, but significantly 
elevated extracellular glutamate. (C,D) Intra-NAc local perfusion of the selective CB1 antagonist SR141716A 
also failed to alter extracellular DA, but significantly elevated extracellular glutamate. (E,F) Intra-NAc local 
perfusion of SR141716A prior to MPEP failed to alter NAc DA (E), but blocked MPEP-enhanced extracellular 
glutamate (F). *p < 0.05, **p < 0.01, compared to pre-SR141716A baseline.
www.nature.com/scientificreports/
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administration of MPEP into the NAc significantly inhibits cocaine self-administration under FR2 and/or PR 
reinforcement schedules, oral sucrose self-administration under PR reinforcement, as well as cocaine-induced 
reinstatement of drug-seeking behaviors. This is consistent with previous reports that pretreatment with 
Figure 6. Effects of MPEP on extracellular DA and glutamate and cocaine self-administration in WT and 
CB1-KO mice. (A,B) Systemic administration of MPEP (10 mg/kg, i.p.) failed to alter extracellular DA in both 
genotypes of mice (A), while significantly increased extracellular glutamate in the NAc of WT mice, but not in 
CB1-KO mice. (C,D) Systemic administration of MPEP dose-dependently inhibited cocaine self-administration 
in WT mice, but not in CB1-KO mice. (E,F) Time course of mouse cocaine self-administration within daily 3 h 
session, illustrating that MPEP significantly inhibited cocaine self-administration in the first hour of cocaine 
self-administration in WT mice (E), but not in CB1-KO mice (F). *p < 0.05, **p < 0.01, compared to pre-MPEP 
baseline; #p < 0.05, compared to vehicle control group (B).
www.nature.com/scientificreports/
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MPEP or other mGluR5 antagonists (MTEP, fenobam, MFZ 10-7) inhibit cocaine self-administration1,3,4,6–9 or 
cocaine-induced reinstatement of drug-seeking behavior7–11,34,35. Surprisingly, MPEP, at the same or higher doses, 
neither altered oral sucrose self-administration under FR2 reinforcement nor reinstatement of cocaine-seeking 
behavior triggered by cocaine-associated cues or footshock stress. This is different from previous reports that the 
mGluR5 antagonist MPEP inhibits cue-induced reinstatement of cocaine-seeking11,34 and that MTEP inhibits 
footshock-stress-induced reinstatement responding36. The mechanisms underlying these apparently conflicting 
findings are unclear. It may be related to the differences in the experimental conditions, drug doses, receptor 
binding affinity and other pharmacokinetic profiles of different mGluR5 ligands, or in the neural substrates 
underlying reinstatement of drug-seeking behaviors triggered by three distinct factors.
Whatever the reasons for the disparate findings in cue- or stress-induced reinstatement models, the focus 
of the present study was to understand the mechanisms by which mGluR5 antagonism inhibits cocaine 
self-administration or reinforcement. It is well documented that cocaine significantly elevates extracellular DA 
and glutamate within the NAc13,14,37–40, which has been thought to underlie cocaine self-administration and 
cocaine-induced reinstatement of drug-seeking. In the present study, we found that MPEP pretreatment failed 
to alter cocaine-induced increases in extracellular DA, but significantly attenuated cocaine-enhanced glutamate 
release, suggesting that a presynaptic glutamate mechanism may be involved. However, it is unclear how such 
an increase in NAc glutamate mediates cocaine reinforcement and cocaine-induced reinstatement responding.
A majority of recent studies have focused on the role of postsynaptic AMPA and NMDA receptors in relapse 
to drug-seeking behaviors2,41,42. mGluR5s are co-localized with DA D2 and NMDA receptors on striatal MSNs43,44 
and mGluR5 activation enhances NMDA receptor-mediated responses to glutamate24,45–47. Therefore, one pos-
sible mechanism by which mGluR5 blockade attenuates cocaine-seeking behaviors is through reducing NMDA 
receptor activation by glutamate. This hypothesis was supported by one study demonstrating that mGluR5 acti-
vation produces mild depolarization and enhanced excitability of MSNs in the NAc48, but is not supported by 
another study47. A second possibility is that mGluR5 activation may increase AMPA receptor trafficking42, caus-
ing increased surface expression of GluA1-containing high-conduction AMPA receptors in the NAc42,49,50. In 
addition, mGluR5 activation increases phosphorylation of AMPA receptor GluA1 subunits51,52, which facilitates 
glutamate transmission42. Accordingly, mGluR5 blockade would lower AMPA receptor responses to glutamate, 
contributing to antagonism of cocaine-taking and cocaine-seeking behaviors. However, no direct evidence sup-
ports this conjecture.
A third possibility is the current eCB retrograde signaling hypothesis: mGluR5 activation results in eCB 
release, which subsequently activates presynaptic CB1 receptors and inhibits presynaptic Ca++-dependent vesic-
ular glutamate release26,29,32,53–55. Accordingly, mGluR5 blockade should produce an increase in extracellular 
glutamate, which subsequently inhibits cocaine-induced glutamate release, thereby attenuating reinstatement of 
drug-seeking behavior. This hypothesis is supported by our findings: (1) systemic or local administration of the 
mGluR5 antagonist MPEP increased extracellular glutamate, not DA. (2) MPEP pretreatment dose-dependently 
inhibited cocaine-induced increases in extracellular glutamate and cocaine-induced reinstatement of 
drug-seeking behavior; (3) the CB1 receptor antagonist SR141716A alone produced an increase in glutamate 
similar to MPEP, and not DA. (4) Blockade of NAc CB1 receptors prevented MPEP-enhanced glutamate release 
(in the present study) and attenuated cocaine-enhanced glutamate release and cocaine-induced reinstate-
ment39; (5) MPEP-enhanced glutamate is Ca++-dependent; and (6) genetic disruption of CB1 receptors blocks 
MPEP-enhanced extracellular glutamate and MPEP-induced inhibition of cocaine self-administration. Taken 
together, these findings suggest that a retrograde eCB-CB1 receptor mechanism may underlie MPEP-induced 
increases in extracellular glutamate and the antagonism of cocaine self-administration and cocaine-primed 
reinstatement.
We previously reported that blockade of CB1 receptors by AM251 or activation of mGluR7 by AMN082 
elevates extracellular glutamate in the NAc, which subsequently inhibits cocaine-induced glutamate release and 
reinstatement of drug-seeking by activation of presynaptic mGluR2/3 autoreceptors14,39. Similarly, elevation of 
extracellular NAc glutamate by inhibition of cysteine-glutamate exchange also suppresses cocaine-induced rein-
statement of drug-seeking via activation of mGluR2/337,41. Therefore, we believe a fourth possibility is that this 
glutamate-mGluR2/3 mechanism could underlie the antagonism of MPEP on cocaine-induced reinstatement of 
drug-seeking behavior in the present study. Finally, rats treated chronically with cocaine display decreased basal 
levels of extracellular glutamate in the NAc12,13,38,39, which has been thought to contribute to craving and relapse to 
drug-seeking behavior56. Thus, MPEP-enhanced glutamate release may restore basal levels of extracellular gluta-
mate in cocaine self-administering rats, and therefore, reduce drug craving and relapse to drug-seeking behavior.
We note that MPEP pretreatment selectively blocked cocaine-enhanced extracellular glutamate, but failed to 
alter cocaine-enhanced extracellular DA. Accordingly, MPEP pretreatment should have no significant effect on 
cocaine self-administration since drug self-administration is largely DA-dependent56. However, we have recently 
reported that genetic deletion of presynaptic mGluR2 autoreceptors significantly elevated extracellular gluta-
mate, which produced a significant reduction in cocaine self-administration and cocaine reinforcement57. While 
enhanced glutamate release may increase excitability of MSNs by activation of NMDA and/or AMPA recep-
tors58, enhanced DA produces an inhibitory effect on the MSNs mainly by activation of DA D2-like receptors59. 
Therefore, we propose that enhanced glutamate release may functionally antagonize DA action in postsynaptic 
MSNs, and subsequently attenuate cocaine self-administration under both FR2 and PR reinforcement in the 
present study.
Surprisingly, we found that the mGluR5 antagonist MPEP significantly increased extracellular glutamate, 
while the mGluR5 agonist CHPG had no significant effect, suggesting that mGluR5s are tonically activated by 
endogenous glutamate. This may well explain why cocaine exposure significantly blunts or eliminates mGluR5 
agonist-induced long-term depression in NAc neurons60–63. Since cocaine exposure may increase glutamate 
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release in the NAc, glutamate tone on mGluR5s would also be elevated and thus receptor availability to mGluR5 
agonists would be reduced64.
In conclusion, the most important finding of the present study is that a presynaptic glutamate/CB1 mecha-
nism may underlie the therapeutic anti-cocaine effects of mGluR5 antagonists in animal models of drug reward 
and relapse. Cocaine use or priming elevates extracellular NAc DA and glutamate, which subsequently activates 
DA (D1, D2) and glutamate (AMPA, NMDA) receptors, producing drug reward or relapse to drug-seeking 
behavior after cocaine abstinence. We found that mGluR5 antagonism elevates extracellular glutamate via a ret-
rograde eCB-CB1 receptor mechanism. Enhanced glutamate, on the one hand, activates presynaptic mGluR2/3 
autoreceptors and subsequently inhibits cocaine-induced glutamate release. On the other hand, enhanced gluta-
mate may also activate postsynaptic NMDA and AMPA receptors in MSNs, which functionally antagonizes the 
inhibitory effect of DA on MSNs and the subsequent cocaine self-administration and relapse to drug-seeking 
behavior. Together, the present study provides new evidence supporting our recent finding57 that enhanced 
glutamate release in the NAc may functionally antagonizes the action produced by DA, causing a reduction in 
cocaine-taking and cocaine-seeking behaviors.
Materials and Methods
Animals. Male Long-Evans rats (Charles River, Raleigh, NC, USA) and two genotypes of mice (wild-type 
and CB1−/−) were used in this study. Animals were housed individually in a climate-controlled room on a reverse 
light–dark cycle (lights on at 1900 hours, lights off at 0700 hours) with ad libitum access to food and water. All 
experimental procedures were conducted in accordance with the Guide for the Care and Use of Laboratory 
Animals (US National Academy of Sciences), and were approved by the Animal Care and Use Committee of the 
National Institute on Drug Abuse of the US National Institutes of Health. The animal facility was accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International.
Experiment 1: Cocaine self-administration in rats. Surgery. The i.v. surgery and cocaine 
self-administration procedures are the same as we reported previously14,39. After recovery from surgery, each 
rat was placed into a test chamber (day time - dark phase) and allowed to lever-press for i.v. cocaine (1 mg/
kg/infusion) delivered in 0.08 ml over 4.6 sec, on a fixed ratio 1 (FR1) reinforcement schedule. Each cocaine 
infusion was associated with presentation of a stimulus light and tone. During the 4.6 sec infusion time, addi-
tional responses on the active lever were recorded but did not lead to additional infusions. Each session lasted 
3 hr. FR1 reinforcement was used for 5–7 days. Then subjects were allowed to continue cocaine (0.5 mg/kg/
infusion) self-administration under FR2 reinforcement until stable cocaine self-administration was established: 
operationally defined as a minimum of 20 presses on the active lever per test session, less than 10% variability in 
inter-response interval, less than 10% variability in number of infusions taken, and less than 10% variability in 
number of presses on the active lever for at least 3 consecutive days. To avoid cocaine overdose, each animal was 
limited to a maximum of 50 cocaine injections per 3 hr session.
Evaluating the effects of MPEP on cocaine self-administration. We first evaluated the effects of systemic adminis-
tration of MPEP (10, 20 mg/kg, i.p., 30 min prior to testing) or vehicle (saline) on FR2 cocaine self-administration 
in three group of rats (between-subjects design, n = 6–8/group). Effects of MPEP on cocaine self-administration 
were assessed by comparing mean numbers of total cocaine infusions during test sessions. Then the same groups 
of animals continued cocaine self-administration. After stable self-administration was achieved, the animals were 
divided into three dose groups again to evaluate the effects of intra-NAc microinjection of MPEP (0, 1 3 μg/side) 
on cocaine self-administration.
Evaluating the effects of MPEP on cocaine self-administration under progressive-ratio reinforcement. Initial 
cocaine self-administration under FR1 and FR2 reinforcement schedules was identical to that outlined above. 
After stable cocaine self-administration under FR2 reinforcement was established, the subjects were switched 
to cocaine self-administration (0.5 mg/kg/infusion) under a PR schedule, during which the work requirement 
of lever presses needed to receive a single i.v. cocaine infusion was progressively raised within each test ses-
sion according to the following PR series: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 
268, 328, 402, 492 and 603 until the break point was reached31. The break-point was defined as the maximal 
workload (i.e. number of lever presses) completed for the last cocaine infusion prior to a 1-h period during 
which no infusions were obtained by the animal. Animals were allowed to continue daily sessions of cocaine 
self-administration under PR reinforcement conditions until day-to-day variability in break point fell within 1–2 
ratio increments for 3 consecutive days. Once a stable break-point was established, subjects were assigned to three 
subgroups to determine the effects of four different doses of MPEP (10, 20 mg/kg, i.p.) or vehicle (1 ml/kg of 25% 
2-hydroxypropyl-β-cyclodextrin solution) on PR break-point for cocaine self-administration.
Evaluating the effects of MPEP on oral sucrose self-administration. The procedures for sucrose self-administration 
were identical to the procedures for cocaine self-administration except for the following: (1) no surgery was 
performed on the animals; (2) active lever presses led to delivery of 0.1 ml of 5% sucrose solution into a liq-
uid food tray on the operant chamber wall along with presentation of a stimulus light and tone; and (3) each 
self-administration session lasted 1 hr and was capped at 100 deliveries. After stable sucrose self-administration 
was established, the effects of MPEP on oral sucrose self-administration under FR2 reinforcement were deter-
mined in one group of rats (n = 12, within-subject design). Additional group of animals (n = 10) were trained 
for daily sucrose self-administration first under FR2 reinforcement for 5 days and then continued for sucrose 
self-administration under PR reinforcement until the stable self-administration was re-established. The effects of 
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MPEP on break-point for sucrose self-administration were assessed in this group of rats. Each animal was tested 
three times with different drug doses. The time intervals between testing were 2–5 days.
Experiment 2: Reinstatement of drug-seeking behavior. After the completion of Experiment 1, 
animals continued cocaine self-administration until stable self-administration was reestablished. Then, the ani-
mals underwent extinction training, during which cocaine was replaced by saline and the light and sound cues 
that previously accompanied cocaine infusions were turned off. After drug-seeking behavior was extinguished 
– defined as ≤10 active lever presses during each 3 hr session for at least 3 consecutive days – the animals were 
divided into three groups to observe the effects of MPEP pretreatment on reinstatement of drug-seeking behavior 
triggered by cocaine priming, cues, or footshock stress, respectively.
Cocaine-induced reinstatement. On the reinstatement test day, the rats were randomly divided into three dose 
groups (between-subjects design, n = 6–8 per group). Each group of animals received vehicle, 10 mg/kg, 20 mg/
kg, or 30 mg/kg MPEP (i.p.), respectively, 30 min prior to cocaine priming (10 mg/kg, i.p.). Then, the animals were 
placed into the operant chambers in which they previously self-administered cocaine. Reinstatement conditions 
were identical to those in the extinction sessions, i.e., active lever presses were recorded without drug infusions 
or accompanying cues for 3 hr. Effects of MPEP on cocaine-induced reinstatement were assessed by comparing 
mean numbers of cocaine infusions and active lever presses per test session.
Cue-induced reinstatement. Cue-induced reinstatement testing began 24 h after rats met the above extinction 
criterion65. During the testing, 1–2 non-contingent presentations of the cocaine-associated light and tone were 
given at the onset of the test session because toward the end of extinction training, most rats did not approach 
the lever. Subsequent lever presses then led to response-contingent deliveries of the same conditioned light-tone 
cues. On the test day, the animals were divided into 4 dose groups. The effects of vehicle or MPEP pretreatment 
(10 mg/kg, 20 mg/kg, or 30 mg/kg, i.p., 30 min prior to testing) on cue-induced reinstatement of drug-seeking 
behavior were evaluated.
Footshock stress-induced reinstatement. This experiment was conducted in additional 4 groups of rats. The ini-
tial cocaine self-administration was the same as described above. After extinction criteria were met, each group 
of the animals received either vehicle or one dose of MPEP (10, 20, 30 mg/kg, 30 min prior to testing). Then the 
rats were returned to the testing chambers and were exposed to 10 min of intermittent footshock stress (0.5 mA; 
0.5 sec on; mean off period of 40 sec)66, delivered by a computer-controlled system. Following termination of 
footshock, reinstatement testing began with onset of the house light and introduction of the active and inactive 
levers. During each reinstatement test session, conditions were identical to those in extinction sessions. Each 
reinstatement test session lasted 3 hours.
Experiment 3: In vivo microdialysis. The intracranial guide cannula implantation surgery procedures are 
the same as we reported previously14,39. The effects of MPEP and cocaine on NAc DA and glutamate were assessed 
in rats with the same cocaine self-administration history (1–7 days after the last cocaine self-administration 
session). Additional groups of rats had only intracranial guide cannulae implantation and were used to study 
the effects of other drugs such as MPEP, CHPG, SR141716A, TTX or ω-conotoxin GVIA alone on NAc DA and 
glutamate in drug naïve rats.
Additionally, to determine CB1 receptor involvement in MPEP’s action, wild-type (WT) mice and CB1-KO 
mice were surgically implanted with intracranial guide cannulae (MAB 4.15.IC, SciPro Inc., Sanborn, NY, USA) 
into the NAc. The surgery was performed under an anesthetic mixture of ketamine hydrochloride (80 mg/ml) 
and xylazine hydrochloride (12 mg/ml), using standard aseptic surgical and stereotaxic technique. The stereotaxic 
coordinates for the NAc were AP + 1.4 mm, ML ± 1.5 mm, DV −3.8 mm with an angle of 8° from vertical. The 
guide cannulae were fixed to the skull with dental acrylic. In vivo brain microdialysis was performed 5–7 days 
after the surgery.
Microdialysis procedure. The night before the experiment, concentric microdialysis probes were inserted into 
the NAc14,39. At 2 hrs after the start of perfusion, microdialysis samples were collected every 20 min into 10 µl 
0.1 M perchloric acid to prevent DA degradation. Multiple doses or concentrations of MPEP or CHPG were 
administered alone or in combination with other drugs. Dosage ranges of the various drugs were based upon 
the relative EC50 or IC50 values for binding to the respective targets. MPEP, CHPG, and tetrodotoxin (TTX) were 
purchased from Tocris, and ω-conotoxin GVIA was obtained from Sigma-RBI. All the drugs were dissolved with 
filtered dialysis buffer and were freshly prepared on day of the experiment.
After collection, samples were frozen at −80 °C.
After completion of the microdialysis experiments, rats or mice were deeply anesthetized with a high dose of 
pentobarbital and perfused transcardially with 0.9% saline followed by 10% formalin. Brains were removed and 
placed in 10% formalin for histological verification of microdialysis probe locations in the brain.
Quantification of DA and glutamate. Dialysate DA was measured using the ESA electrochemical detection sys-
tem (ESA Inc., Chelmsford, MA, USA)14 and dialysate glutamate was determined using HPLC with fluorometric 
detection39. The AUC of the glutamate peak was measured using an “EZChrom Elite” ESA chromatography data 
system. DA and glutamate values were quantified with external standard curves.
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Experiment 4: Immunohistochemistry. After the completion of reinstatement testing, a group of rats 
were used to examine mGluR5 expression in rats after cocaine self-administration and extinction. After brain 
perfusion, the brains were removed and placed in 20% sucrose phosphate buffer at 4 °C overnight. Coronal 
sections were cut at 10 μm on a cryostat (CM3050S, Leica Microsystems, Nussloch, Germany). Brain sections 
containing the striatum were blocked and floated in 5% bovine serum albumin (BSA) and 0.5% Triton X-100 
phosphate buffer for 2 hr at room temperature before being incubated with primary antibodies.
IHC assays were performed using mGluR5 antibody (Millipore, Cat#: MABN 540, 1:200) and an astrocyte 
marker (GFAP antibody, Abcam, Cat#: ab7260, 1:500) to detect mGluR5-immunostaining in the NAc. After 
washes, sections were further incubated with a mixture of secondary antibodies – Alexa Fluor 488 goat anti-rabbit 
for mGluR5 and Alexa Fluor 568 goat anti-mouse for GFAP – in 5% BSA and 0.5% Triton X-100 phosphate buffer 
at room temperature for 2 hrs. Sections were then washed, mounted, and cover slipped. Fluorescent images were 
collected with an Olympus FV1000 Confocal System (Olympus) using manufacturer-provided software.
Experiment 5: Cocaine self-administration in mice. Intravenous catheterization surgery and 
self-administration procedures were the same as described previously67,68. After 5–7 days of recovery from sur-
gery, each mouse was placed into a test chamber (Med Associates, Fairfax, VT, USA) and allowed to lever-press 
for i.v. cocaine (0.5 mg/kg/infusion). Each lever press led to a delivery of 0.015 ml of the drug solution over 4.2 sec-
onds under an FR1 reinforcement schedule. Each session lasted 3 hr or until the animal received the maximally 
allowed 50 drug infusions (to prevent drug overdose). Daily drug self-administration continued until stable 
day-to-day operant behavior was established with a steady behavioral response pattern for at least 3 consecutive 
days. The total numbers of cocaine infusions, the numbers of cocaine self-administrations during every 20-min 
interval, and the numbers of cocaine infusions within the first hour of the self-administration session were com-
pared between WT and CB1-KO mice before and after MPEP administration.
Data analysis. All data are presented as means ± SEM. One-way or two-way repeated measures ANOVA was 
used to determine the significance of the changes in each measure. Whenever a significant main effect was found, 
individual group comparisons were carried out using the Student-Newman-Keuls Method. The significance of 
the results was set at p < 0.05.
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